iRhythm Technologies Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" iRhythm Technologies stock.
View analyst ratings for iRhythm Technologies or view top-rated stocks.

10 Wall Street analysts have issued 12 month price objectives for iRhythm Technologies' stock. Their IRTC stock forecasts range from $105.00 to $165.00. On average, they anticipate iRhythm Technologies' share price to reach $146.18 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price.
View analysts' price targets for iRhythm Technologies or view top-rated stocks among Wall Street analysts.

iRhythm Technologies' stock was trading at $117.69 at the start of the year. Since then, IRTC shares have decreased by 1.0% and is now trading at $116.55.
View the best growth stocks for 2022 here.

iRhythm Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for iRhythm Technologies.

iRhythm Technologies, Inc. (NASDAQ:IRTC) posted its earnings results on Thursday, May, 5th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $0.26. The company earned $92.40 million during the quarter, compared to the consensus estimate of $86.76 million. iRhythm Technologies had a negative net margin of 36.43% and a negative trailing twelve-month return on equity of 34.55%. The company's revenue was up 24.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.95) earnings per share.
View iRhythm Technologies' earnings history.

iRhythm Technologies issued an update on its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $410.00 million-$420.00 million, compared to the consensus revenue estimate of $407.15 million.

20 employees have rated iRhythm Technologies CEO Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among iRhythm Technologies' employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to iRhythm Technologies include Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Inari Medical (NARI), Haemonetics (HAE), Merit Medical Systems (MMSI), Axonics (AXNX) and NuVasive (NUVA).
View all of IRTC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

iRhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

iRhythm Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (10.15%), Vanguard Group Inc. (9.11%), BlackRock Inc. (7.03%), Capital Research Global Investors (4.74%), Mackenzie Financial Corp (3.95%) and Invesco Ltd. (2.70%). Company insiders that own iRhythm Technologies stock include Daniel G Wilson, David A Vort, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends for iRhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Wellington Management Group LLP, Vident Investment Advisory LLC, Bank of New York Mellon Corp, Blair William & Co. IL, Eversept Partners LP, Sands Capital Management LLC, and State Street Corp. Company insiders that have sold iRhythm Technologies company stock in the last two years include Daniel G Wilson, David A Vort, Douglas Devine, Kevin M King, Mark J Day, and Merz Cathleen Noel Bairey.
View insider buying and selling activity for iRhythm Technologies or view top insider-selling stocks.

IRTC stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Capital Research Global Investors, Atika Capital Management LLC, Eminence Capital LP, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Invesco Ltd., and Lisanti Capital Growth LLC.
View insider buying and selling activity for iRhythm Technologies or or view top insider-buying stocks.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRTC stock can currently be purchased for approximately $116.55.

iRhythm Technologies (NASDAQ:IRTC) has a market capitalization of $3.47 billion and generates $322.83 million in revenue each year. The company earns $-101.36 million in net income (profit) each year or ($4.210010) on an earnings per share basis.

iRhythm Technologies employs 1,700 workers across the globe.

iRhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The official website for iRhythm Technologies is www.irhythmtech.com. The company can be reached via phone at (415) 632-5700 or via email at [email protected].